What are the recommended sumatriptan dosing, repeat dosing limits, and contraindications for children and adolescents (≥12 years old, ≥30 kg) with migraine?

Sumatriptan in Pediatric Population

For adolescents aged 12-17 years with migraine, sumatriptan nasal spray (10-20 mg) is the most effective formulation, while oral sumatriptan has not demonstrated efficacy superior to placebo in this age group. 1, 2

Age and Weight Restrictions

Sumatriptan is NOT recommended for children under 12 years of age. 3 The FDA label explicitly states that safety and effectiveness in pediatric patients have not been established, and sumatriptan tablets are not recommended for use in patients younger than 18 years. 3

For adolescents 12-17 years:

• Nasal spray formulations are approved and most effective 1, 2
• Oral formulations (25-100 mg) failed to demonstrate superiority over placebo in five controlled trials involving 701 adolescents 3

Recommended Dosing by Route

Nasal Spray (Preferred Route)

Initial dose:

• 20 mg for adolescents ≥40 kg 4, 5
• 10 mg for adolescents 20-39 kg 4, 5
• 5 mg for adolescents <25 kg (limited data) 5

Repeat dosing:

• May repeat after 2 hours if headache recurs 6, 7
• Maximum: 2 doses (40 mg total) per 24 hours 8, 6
• Must have 24-hour headache-free period between treated attacks 6

Subcutaneous (Adult Dosing - Use with Caution)

While not specifically approved for adolescents, if used:

• 6 mg subcutaneous (adult dose) 8
• May repeat once after 1 hour
• Maximum: 12 mg per 24 hours 8

Oral (NOT Recommended for Adolescents)

Despite being studied at 25-100 mg doses, oral sumatriptan failed to show efficacy over placebo in adolescents 3, 9 and should not be used in this population.

Contraindications (Same as Adults)

Absolute contraindications: 8

• Ischemic vascular conditions (coronary artery disease, peripheral vascular disease)
• Vasospastic coronary disease (Prinzmetal's angina)
• Uncontrolled hypertension
• Hemiplegic or basilar migraine
• Use within 24 hours of ergotamine derivatives or another triptan
• Use within 2 weeks of MAOIs
• Severe hepatic impairment
• History of stroke or transient ischemic attack

Relative contraindications:

• Cardiovascular risk factors requiring evaluation before use 3
• Pregnancy (Category C - use only if benefit justifies risk) 3

Critical Safety Considerations

Serious Adverse Events in Pediatrics

Postmarketing surveillance has documented serious reactions in children and adolescents: 3

• Stroke
• Visual loss
• Death
• Myocardial infarction (reported in a 14-year-old male within 1 day of oral sumatriptan use) 3

Common Adverse Events

Most frequent with nasal spray: 6, 7

• Taste disturbance (19-25% vs 2% placebo)
• Nausea
• Throat discomfort
• Nasal discomfort

Important: Adverse events appear to be both dose- and age-dependent, with younger patients reporting reactions more commonly than older adolescents. 3

Clinical Pearls

Stepped care approach for adolescents: 1, 2

1. First-line: Ibuprofen (weight-appropriate dosing)
2. Second-line: Sumatriptan nasal spray or zolmitriptan nasal spray if NSAIDs fail
3. Consider domperidone for nausea in adolescents 12-17 years 1

Medication overuse headache prevention:

• Limit acute medication use to <10 days per month 10
• Monitor frequency of sumatriptan use closely

Trial before abandonment:

• Patients should try medication for 2-3 headache episodes before concluding ineffectiveness 8
• If one triptan fails, consider trying a different triptan 8

Timing matters:

• Treat early when pain is mild for better efficacy 8, 11
• Nasal spray provides faster relief than oral formulations 8

Evidence Limitations

The high placebo response rate in pediatric migraine trials (often >50%) confounds the evidence base 1, which explains why triptans have not consistently demonstrated benefit in children despite biological plausibility. This does not mean they are ineffective in real-world practice, but rather that clinical trials struggle to demonstrate superiority over placebo in this population.